Interferons: Success in anti-viral immunotherapy
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
The interferons (IFNs) are glycoproteins with strong antiviral activities that represent one of the first lines of host defense against invading pathogens. These proteins are classified into three groups, Type I, II and III IFNs, based on the structure of their receptors on the cell surface. Due to their ability to modulate immune responses, they have become attractive therapeutic options to control chronic virus infections. In combination with other drugs, Type I IFNs are considered a “standard of care” in suppressing Hepatitis C (HCV) and Hepatitis B (HBV) infections, while Type III IFN has generated encouraging results as a treatment for HCV infection in phase III clinical trials. However, though effective, using IFNs as a treatment is not without the need for caution. IFNs are such powerful cytokines that affect a wide array of cell types; as a result, patients usually experience unpleasant symptoms, with a percentage of patients suffering system wide effects. Thus, constant monitoring is required for patients treated with IFN in order to reach the treatment goals of suppressing virus infection and maintaining quality of life.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interferon-γ: an overview of signals, mechanisms and functions
Schroder, K., Hertzog, P. J., Ravasi, T., & Hume, D. A. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.0603252 · Cited by 4,120 · cited 1×
“with IFN-g R2, that then initiates the downstream signaling events [36].”
BackgroundRegulation of type I interferon responses
Ivashkiv, L. B., & Donlin, L. T. (2014) · Nature Reviews Immunology · doi:10.1038/nri3581 · Cited by 3,297
Lavanchy, D. (2004) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.2003.00487.x · Cited by 2,642
IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex
Kotenko, S. V., Gallagher, G., Baurin, V. V., Lewis-Antes, A., Shen, M., Shah, N. K., Langer, J. A., Sheikh, F., Dickensheets, H., & Donnelly, R. P. (2003) · Nature Immunology · doi:10.1038/ni875 · Cited by 1,868
(2012) · Hepatogastroenterology · doi:10.5754/hge12183 · Cited by 1,625
Type I Interferons in Host Defense
Stetson, D. B., & Medzhitov, R. (2006) · Immunity · doi:10.1016/j.immuni.2006.08.007 · Cited by 1,195
TYPE I INTERFERONS (α/β) IN IMMUNITY AND AUTOIMMUNITY
Theofilopoulos, A. N., Baccala, R., Beutler, B., & Kono, D. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115843 · Cited by 1,185
Immunomodulatory functions of type I interferons
González-Navajas, J. M., Lee, J., David, M., & Raz, E. (2012) · Nature Reviews Immunology · doi:10.1038/nri3133 · Cited by 1,011
Sommereyns, C., Paul, S., Staeheli, P., & Michiels, T. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.1000017 · Cited by 772
Complex modulation of cell type-specific signaling in response to type I interferons
van Boxel-Dezaire, A. H. H., Rani, M. R. S., & Stark, G. R. (2006) · Immunity · doi:10.1016/j.immuni.2006.08.014 · Cited by 530 · cited 1×
“In addition to STAT1, STAT2 and STAT3, it has been shown that Type I IFN can also activate STAT4, STAT5 and STAT6 in certain cell types [4].”
BackgroundLambda Interferon Inhibits Hepatitis B and C Virus Replication
Robek, M. D., Boyd, B. S., & Chisari, F. V. (2005) · Journal of Virology · doi:10.1128/jvi.79.6.3851-3854.2005 · Cited by 431
Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C Virus
Rong, L., Dahari, H., Ribeiro, R. M., & Perelson, A. S. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000544 · Cited by 355
Doyle, S. E., Schreckhise, H., Khuu‐Duong, K., Henderson, K., Rosler, R., Storey, H., Yao, L., Liu, H., Barahmand‐pour, F., Sivakumar, P., et al. (2006) · Hepatology · doi:10.1002/hep.21312 · Cited by 348
Gene modulation and immunoregulatory roles of Interferonγ
Saha, B., Jyothi Prasanna, S., Chandrasekar, B., & Nandi, D. (2010) · Cytokine · doi:10.1016/j.cyto.2009.11.021 · Cited by 300
Dumoutier, L., Tounsi, A., Michiels, T., Sommereyns, C., Kotenko, S. V., & Renauld, J.-C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404789200 · Cited by 291
Jarvis, J. N., Meintjes, G., Rebe, K., Williams, G. N., Bicanic, T., Williams, A., Schutz, C., Bekker, L.-G., Wood, R., & Harrison, T. S. (2012) · AIDS · doi:10.1097/qad.0b013e3283536a93 · Cited by 290
IFNγ signaling—Does it mean JAK–STAT?
Gough, D. J., Levy, D. E., Johnstone, R. W., & Clarke, C. J. (2008) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2008.08.004 · Cited by 289
Long-Term Interferon- Therapy for Patients with Chronic Granulomatous Disease
Marciano, B. E., Wesley, R., De Carlo, E. S., Anderson, V. L., Barnhart, L. A., Darnell, D., Malech, H. L., Gallin, J. I., & Holland, S. M. (2004) · Clinical Infectious Diseases · doi:10.1086/422993 · Cited by 251
Kwon, H., & Lok, A. S. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.33 · Cited by 250
Muir, A. J., Shiffman, M. L., Zaman, A., Yoffe, B., de la Torre, A., Flamm, S., Gordon, S. C., Marotta, P., Vierling, J. M., Carlos Lopez-Talavera, J., et al. (2010) · Hepatology · doi:10.1002/hep.23743 · Cited by 249
Rini, B. I., Bellmunt, J., Clancy, J., Wang, K., Niethammer, A. G., Hariharan, S., & Escudier, B. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.5305 · Cited by 212
Witte, K., Gruetz, G., Volk, H.-D., Looman, A. C., Asadullah, K., Sterry, W., Sabat, R., & Wolk, K. (2009) · Genes & Immunity · doi:10.1038/gene.2009.72 · Cited by 198
Interferon-λ Is Functionally an Interferon but Structurally Related to the Interleukin-10 Family
Gad, H. H., Dellgren, C., Hamming, O. J., Vends, S., Paludan, S. R., & Hartmann, R. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.002923 · Cited by 196
Simonsson, B., Gedde-Dahl, T., Markevärn, B., Remes, K., Stentoft, J., Almqvist, A., Björeman, M., Flogegård, M., Koskenvesa, P., Lindblom, A., et al. (2011) · Blood · doi:10.1182/blood-2011-02-336685 · Cited by 194
Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C
Sulkowski, M., Cooper, C., Hunyady, B., Jia, J., Ogurtsov, P. P., Peck‐Radosavljevic, M., Shiffman, M. L., Yurdaydın, C., & Dalgård, O. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.21 · Cited by 175
IFN‐α subtypes: distinct biological activities in anti‐viral therapy
Gibbert, K., Schlaak, J., Yang, D., & Dittmer, U. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12010 · Cited by 174
Zhao, H. L., Yao, X. Q., Xue, C., Wang, Y., Xiong, X. H., & Liu, Z. M. (2008) · Protein Expression and Purification · doi:10.1016/j.pep.2008.04.013 · Cited by 168
Structural conservation of interferon gamma among vertebrates
Savan, R., Ravichandran, S., Collins, J., Sakai, M., & Young, H. A. (2009) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.02.006 · Cited by 162
Self-citationThe Significance of Interferon-γ in HIV-1 Pathogenesis, Therapy, and Prophylaxis
Roff, S. R., Noon-Song, E. N., & Yamamoto, J. K. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00498 · Cited by 153
Re-emergence of interferon-α in the treatment of chronic myeloid leukemia
Talpaz, M., Hehlmann, R., Quintás-Cardama, A., Mercer, J., & Cortes, J. (2013) · Leukemia · doi:10.1038/leu.2012.313 · Cited by 137
IFN-α in the Treatment of Melanoma
Tarhini, A. A., Gogas, H., & Kirkwood, J. M. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1290060 · Cited by 133
Brand, S., Zitzmann, K., Dambacher, J., Beigel, F., Olszak, T., Vlotides, G., Eichhorst, S. T., Göke, B., Diepolder, H. M., & Auernhammer, C. J. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.04.004 · Cited by 106
Nelson, D. R., Benhamou, Y., Chuang, W., Lawitz, E., Rodriguez‐Torres, M., Flisiak, R., Rasenack, J. W. F., Kryczka, W., Lee, C., Bain, V. G., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.06.062 · Cited by 104
Direct-Acting Antiviral Agents for Hepatitis C Virus Infection
Kiser, J. J., & Flexner, C. W. (2012) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011112-140254 · Cited by 102
Novel Therapeutic Approaches for Hepatitis C
Au, J. S., & Pockros, P. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.206 · Cited by 95
IFN-λ3 Inhibits HIV Infection of Macrophages through the JAK-STAT Pathway
Liu, M., Zhou, D., Wang, X., Zhou, W., Li, Y., Li, J., Wang, Y.-Z., & Ho, W. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035902 · Cited by 81
Zeuzem, S., Sulkowski, M., Lawitz, E., Rustgi, V. K., Rodriguez‐Torres, M., Bacon, B. R., Grigorescu, M. D., Tice, A. D., Lurie, Y., Cianciara, J., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.06.066 · Cited by 79
Interferon-lambda and therapy for chronic hepatitis C virus infection
Donnelly, R. P., Dickensheets, H. L., & OʼBrien, T. R. (2011) · Trends in Immunology · doi:10.1016/j.it.2011.07.002 · Cited by 76
Pegylated interferons α2a and α2b in the treatment of chronic hepatitis C
Aghemo, A., Rumi, M. G., & Colombo, M. G. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.101 · Cited by 72
Preclinical and Clinical Development of Pegylated Interferon-Lambda 1 in Chronic Hepatitis C
Ramos, E. L. (2010) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2010.0066 · Cited by 57
Boasso, A. (2013) · Scientifica · doi:10.1155/2013/580968 · Cited by 46
Rommer, P. S., & Stüve, O. (2013) · Current Treatment Options in Neurology · doi:10.1007/s11940-013-0233-x · Cited by 33
Tian, R., Guo, H., Wei, J., Yang, C., He, S., & Wang, J. (2012) · Antiviral Research · doi:10.1016/j.antiviral.2012.04.011 · Cited by 33
Sergio Bracarda, A., Porta, C., Boni, C., Santoro, A., Mucciarini, C., Pazzola, A., Cortesi, E., Gasparro, D., Labianca, R., Costanzo, F. D., et al. (2012) · European Urology · doi:10.1016/j.eururo.2012.08.027 · Cited by 32
Therapeutic Perspectives in Atopic Dermatitis
Misery, L. (2010) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-010-8226-y · Cited by 31
Immunotherapeutic interventions in chronic hepatitis B virus infection: A review
Wang, L., Zou, Z. Q., Liu, C. X., & Liu, X. Z. (2014) · Journal of Immunological Methods · doi:10.1016/j.jim.2014.04.004 · Cited by 29
IFN Signaling: How a Non-Canonical Model Led to the Development of IFN Mimetics
Johnson, H. M., Noon-Song, E. N., Dabelic, R., & Ahmed, C. M. I. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00202 · Cited by 28
Goldwater, P. N. (1994) · Vaccine · doi:10.1016/0264-410x(94)90116-3 · Cited by 28
The molecular study of IFNβ pleiotropic roles in MS treatment.
Kay, M., Hojati, Z., & Dehghanian, F. (2013) · PubMed Central · Cited by 25
Piccolo, P., Lenci, I., Paolo, D. D., Demelia, L., Sorbello, O., Nosotti, L., & Angelico, M. (2013) · Antiviral Therapy · doi:10.3851/imp2281 · Cited by 22
Interferon in the treatment of chronic hepatitis C: a drug caught between past and future
Vezali, E., Aghemo, A., & Colombo, M. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.552906 · Cited by 20
Johnson‐Ansah, H., Guilhot, J., Rousselot, P. H., Réa, D., Legros, L., Huguet, F., Nicolini, F. E., Mahon, F., Preudhomme, C., & Guilhot, F. (2013) · Cancer · doi:10.1002/cncr.28328 · Cited by 17
Wu, Y., Cai, W.-M., Li, Q., Liu, Y., Shen, H., Mertens, P. R., Dooley, S., & Weng, H. (2011) · Hepatobiliary & pancreatic diseases international · doi:10.1016/s1499-3872(11)60024-6 · Cited by 15
Cited by
SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling
Miorin, L., Kehrer, T., Sanchez-Aparicio, M. T., Zhang, K., Cohen, P., Patel, R. S., Cupic, A., Makio, T., Mei, M., Moreno, E., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2016650117 · Cited by 527
Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV
Lokugamage, K. G., Hage, A., de Vries, M., Valero-Jimenez, A. M., Schindewolf, C., Dittmann, M., Rajsbaum, R., & Menachery, V. D. (2020) · Journal of Virology · doi:10.1128/jvi.01410-20 · Cited by 483
Zinc and respiratory tract infections: Perspectives for COVID‑19 (Review)
Skalny, A., Rink, L., Ajsuvakova, O., Aschner, M., Gritsenko, V., Alekseenko, S., Svistunov, A., Petrakis, D., Spandidos, D., Aaseth, J., et al. (2020) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2020.4575 · Cited by 435
Interferons α and β in cancer: therapeutic opportunities from new insights
Borden, E. C. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0011-2 · Cited by 423
Antiviral peptides as promising therapeutic drugs
Vilas Boas, L. C. P., Campos, M. L., Berlanda, R. L. A., de Carvalho Neves, N., & Franco, O. L. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03138-w · Cited by 336
Metadata
- Authors
- Lin, F.-C., & Young, H. A.
- Venue
- Cytokine & Growth Factor Reviews
- Publisher
- Elsevier BV
- Published
- 2014-08
- Volume
- 25
- Issue
- 4
- Pages
- 369-376
- ISSN
- 1359-6101 (ISSN-L)
- OpenAlex
- W1978329469
- Cited by
- 254
- References
- 53
- FWCI
- 0.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.